hydroxychloroquine has been researched along with Torsade de Pointes in 24 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To analyze the cases of torsade de pointes (TdP) and related symptoms reported in association with chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZT) to the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) using qualitative and quantitative pharmacovigilance approaches." | 8.02 | Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. ( Saint-Gerons, DM; Tabarés-Seisdedos, R, 2021) |
| "To analyze the cases of torsade de pointes (TdP) and related symptoms reported in association with chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZT) to the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) using qualitative and quantitative pharmacovigilance approaches." | 4.02 | Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. ( Saint-Gerons, DM; Tabarés-Seisdedos, R, 2021) |
| "The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy." | 3.96 | Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era. ( Chang, D; Epstein, LM; Fishbein, J; Gabriels, J; Mountantonakis, SE; Qiu, M; Saleh, M, 2020) |
| "The incidence and nature of arrhythmias in the setting of COVID-19 were poorly documented across studies." | 2.72 | Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. ( Amarasekera, AT; Kayes, T; Kodsi, M; MacIntyre, CR; Malaty, M; Tan, TC, 2021) |
| " However, some of these medications have potential cardiac adverse effects." | 2.66 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020) |
| " Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used." | 1.62 | Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. ( Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A, 2021) |
| "Hydroxychloroquine has been widely prescribed to treat patients with COVID-19 pneumonia." | 1.62 | Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. ( Ali, N; Aslam, W; Lamb, CR, 2021) |
| "One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure." | 1.56 | Early experience with remdesivir in SARS-CoV-2 pneumonia. ( Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 24 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chotsiri, P | 1 |
| Tarning, J | 1 |
| Hoglund, RM | 1 |
| Watson, JA | 1 |
| White, NJ | 1 |
| Roden, DM | 4 |
| Harrington, RA | 3 |
| Poppas, A | 3 |
| Russo, AM | 3 |
| Bauman, JL | 1 |
| Tisdale, JE | 1 |
| Sarayani, A | 1 |
| Cicali, B | 1 |
| Henriksen, CH | 1 |
| Brown, JD | 1 |
| Funck-Brentano, C | 1 |
| Salem, JE | 1 |
| Nguyen, LS | 1 |
| Drici, MD | 1 |
| Giudicessi, JR | 1 |
| Noseworthy, PA | 1 |
| Friedman, PA | 1 |
| Ackerman, MJ | 1 |
| Naksuk, N | 1 |
| Lazar, S | 1 |
| Peeraphatdit, TB | 1 |
| Chorin, E | 2 |
| Wadhwani, L | 2 |
| Magnani, S | 1 |
| Dai, M | 2 |
| Shulman, E | 2 |
| Nadeau-Routhier, C | 1 |
| Knotts, R | 1 |
| Bar-Cohen, R | 2 |
| Kogan, E | 1 |
| Barbhaiya, C | 2 |
| Aizer, A | 2 |
| Holmes, D | 2 |
| Bernstein, S | 2 |
| Spinelli, M | 2 |
| Park, DS | 2 |
| Stefano, C | 1 |
| Chinitz, LA | 3 |
| Jankelson, L | 3 |
| Durante-Mangoni, E | 1 |
| Andini, R | 1 |
| Bertolino, L | 1 |
| Mele, F | 1 |
| Florio, LL | 1 |
| Murino, P | 1 |
| Corcione, A | 1 |
| Zampino, R | 1 |
| Karam, G | 1 |
| Becker, ML | 1 |
| Tsai, MC | 1 |
| Maraj, I | 1 |
| Hummel, JP | 1 |
| Taoutel, R | 1 |
| Chamoun, R | 1 |
| Workman, V | 1 |
| Li, C | 1 |
| Tran, L | 1 |
| DelVecchio, A | 1 |
| Howes, C | 1 |
| Akar, JG | 1 |
| Bun, SS | 2 |
| Taghji, P | 1 |
| Courjon, J | 1 |
| Squara, F | 1 |
| Scarlatti, D | 1 |
| Theodore, G | 1 |
| Baudouy, D | 1 |
| Sartre, B | 1 |
| Labbaoui, M | 1 |
| Dellamonica, J | 1 |
| Doyen, D | 1 |
| Marquette, CH | 1 |
| Levraut, J | 1 |
| Esnault, V | 1 |
| Ferrari, E | 1 |
| Carron, J | 1 |
| Sharif, Z | 1 |
| Hussein, H | 1 |
| Kennedy, M | 1 |
| McAdam, B | 1 |
| Sheahan, R | 1 |
| Wu, TC | 1 |
| Sacilotto, L | 1 |
| Darrieux, FCDC | 1 |
| Pisani, CF | 1 |
| Melo, SL | 1 |
| Hachul, DT | 1 |
| Scanavacca, M | 1 |
| Lalabekyan, B | 1 |
| Kunst, G | 1 |
| Skelton, VA | 1 |
| Saleh, M | 1 |
| Gabriels, J | 1 |
| Chang, D | 1 |
| Fishbein, J | 1 |
| Qiu, M | 1 |
| Mountantonakis, SE | 1 |
| Epstein, LM | 1 |
| Malaty, M | 1 |
| Kayes, T | 1 |
| Amarasekera, AT | 1 |
| Kodsi, M | 1 |
| MacIntyre, CR | 1 |
| Tan, TC | 1 |
| Alkasir, A | 1 |
| Lippmann, S | 1 |
| Ehrlich, H | 1 |
| Elkbuli, A | 1 |
| Aslam, W | 1 |
| Lamb, CR | 1 |
| Ali, N | 1 |
| Saint-Gerons, DM | 1 |
| Tabarés-Seisdedos, R | 1 |
5 reviews available for hydroxychloroquine and Torsade de Pointes
| Article | Year |
|---|---|
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
Topics: Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; | 2020 |
QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Death, Su | 2020 |
Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Topics: Anti-Bacterial Agents; Antiviral Agents; Azithromycin; COVID-19 Drug Treatment; Drug Combinations; E | 2021 |
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Atrial Fibrillat | 2021 |
1 trial available for hydroxychloroquine and Torsade de Pointes
| Article | Year |
|---|---|
Torsades de Pointes in Coronavirus Disease 2019 Infection.
Topics: Aged; Antimalarials; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroqu | 2021 |
18 other studies available for hydroxychloroquine and Torsade de Pointes
| Article | Year |
|---|---|
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; DN | 2022 |
Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.
Topics: Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Corona | 2020 |
Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Risk Factors; SARS | 2020 |
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Contraindications, Drug; Coronavirus Infection | 2020 |
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Interactions; D | 2021 |
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-1 | 2020 |
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Topics: Anti-Infective Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Cardiac; Dr | 2020 |
QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
Topics: Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; C | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver | 2020 |
Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin.
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; Incidence; Long QT Syndrome; Pandemics; Patients | 2020 |
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
Topics: Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Electrocardio | 2020 |
QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
Topics: Action Potentials; Adolescent; Adult; Aged; Antiviral Agents; Azithromycin; Cardiotoxicity; COVID-19 | 2020 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular | 2020 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithro | 2021 |
Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
Topics: Aged; Anti-Infective Agents; Citalopram; COVID-19 Drug Treatment; Dexamethasone; Donepezil; Drug The | 2021 |
Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Topics: Adult; Aged; Azithromycin; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquin | 2021 |